Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.51
RTRX's Cash to Debt is ranked lower than
56% of the 711 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.34 vs. RTRX: 1.51 )
Ranked among companies with meaningful Cash to Debt only.
RTRX' s 10-Year Cash to Debt Range
Min: 0.13  Med: 9999.00 Max: No Debt
Current: 1.51
Equity to Asset 0.36
RTRX's Equity to Asset is ranked lower than
83% of the 575 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. RTRX: 0.36 )
Ranked among companies with meaningful Equity to Asset only.
RTRX' s 10-Year Equity to Asset Range
Min: -3.16  Med: -0.33 Max: 0.41
Current: 0.36
-3.16
0.41
F-Score: 4
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -160.65
RTRX's Operating margin (%) is ranked lower than
91% of the 667 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.78 vs. RTRX: -160.65 )
Ranked among companies with meaningful Operating margin (%) only.
RTRX' s 10-Year Operating margin (%) Range
Min: 345.21  Med: 1225.12 Max: 2105.03
Current: -160.65
345.21
2105.03
Net-margin (%) -74.58
RTRX's Net-margin (%) is ranked lower than
89% of the 669 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.89 vs. RTRX: -74.58 )
Ranked among companies with meaningful Net-margin (%) only.
RTRX' s 10-Year Net-margin (%) Range
Min: 345.99  Med: 1202.68 Max: 2059.37
Current: -74.58
345.99
2059.37
ROE (%) -63.50
RTRX's ROE (%) is ranked lower than
89% of the 696 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.30 vs. RTRX: -63.50 )
Ranked among companies with meaningful ROE (%) only.
RTRX' s 10-Year ROE (%) Range
Min: 0  Med: 0.00 Max: 0
Current: -63.5
ROA (%) -13.56
RTRX's ROA (%) is ranked lower than
80% of the 716 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.32 vs. RTRX: -13.56 )
Ranked among companies with meaningful ROA (%) only.
RTRX' s 10-Year ROA (%) Range
Min: -375  Med: -329.94 Max: -142.26
Current: -13.56
-375
-142.26
» RTRX's 10-Y Financials

Financials


Revenue & Net Income
Equity & Asset
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

RTRX Guru Trades in

Q1 2014

RTRX Guru Trades in Q1 2014

Steven Cohen 3,932 sh (New)
Steven Cohen 1,291,474 sh (New)
» More
Q2 2014

RTRX Guru Trades in Q2 2014

Steven Cohen 307,490 sh (-76.19%)
» More
Q2 2015

RTRX Guru Trades in Q2 2015

Jim Simons 80,500 sh (New)
Paul Tudor Jones 26,905 sh (New)
Louis Moore Bacon 85,000 sh (New)
Joel Greenblatt 16,982 sh (New)
Steven Cohen 243,300 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with RTRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 42.92
RTRX's Forward P/E is ranked lower than
78% of the 232 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.58 vs. RTRX: 42.92 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 6.41
RTRX's P/B is ranked lower than
77% of the 644 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.12 vs. RTRX: 6.41 )
Ranked among companies with meaningful P/B only.
RTRX' s 10-Year P/B Range
Min: 2.32  Med: 4.97 Max: 8.33
Current: 6.41
2.32
8.33
P/S 17.85
RTRX's P/S is ranked lower than
90% of the 662 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.13 vs. RTRX: 17.85 )
Ranked among companies with meaningful P/S only.
RTRX' s 10-Year P/S Range
Min: 5.7  Med: 12.22 Max: 22.96
Current: 17.85
5.7
22.96
Days Sales Outstanding 90.05
RTRX's Days Sales Outstanding is ranked lower than
61% of the 598 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 71.39 vs. RTRX: 90.05 )
Ranked among companies with meaningful Days Sales Outstanding only.
RTRX' s 10-Year Days Sales Outstanding Range
Min: 0  Med: 0.00 Max: 0
Current: 90.05

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.44
RTRX's Price/Median PS Value is ranked lower than
58% of the 604 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.28 vs. RTRX: 1.44 )
Ranked among companies with meaningful Price/Median PS Value only.
RTRX' s 10-Year Price/Median PS Value Range
Min: 0.76  Med: 1.25 Max: 1.74
Current: 1.44
0.76
1.74
Earnings Yield (Greenblatt) (%) -7.94
RTRX's Earnings Yield (Greenblatt) (%) is ranked lower than
85% of the 695 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.30 vs. RTRX: -7.94 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RTRX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -36.5  Med: 0.00 Max: 0
Current: -7.94
-36.5
0

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 81 119 160
EPS($) 0.52 0.64 1.08
EPS without NRI($) 0.52 0.64 1.08

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:17R.Germany,
Retrophin Inc was incorporated as Desert Gateway, Inc. as an Oklahoma corporation on February 8, 2008. On February 14, 2013, the Company changed its name to Retrophin, Inc. The Company is a fully integrated biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It is developing Syntocinon Nasal Spray in the U.S. to assist initial postpartum milk ejection, which it refers to as aiding milk let-down, and for the treatment of Schizophrenia and Autism. It is also developing RE-034, a synthetic hormone analogue that is composed of the first 24 amino acids of the 39 amino acids contained in the naturally occurring adrenocorticotrophic hormone, or ACTH, for the treatment of Infantile Spasms, or IS, and Nephrotic Syndrome, or NS. It is developing sparsentan, formerly known as RE-021, a dual acting receptor antagonist of angiotensin and endothelin receptors, for the treatment of focal segmental glomerulosclerosis, or FSGS. The Company competes with Genentech, GlaxoSmithKline, Roche, Novartis, Pfizer, Boehringer Ingelheim, Sanofi, BioMarin, Sarepta, Vertex, and Jazz Pharmaceuticals. The Company is subject to federal, state and local laws governing the use, handling and disposal of these materials.
» More Articles for NAS:RTRX

Headlines

Articles On GuruFocus.com
Retrophin At All-Time High Levels on RE-024 FDA-Status; Syneron Settles Legal Battle Jun 05 2015 
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Retrophin, Inc. Nov 28 2014 
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Retrophin, Inc. Oct 24 2014 
Largest Insider Buys of the Week Apr 07 2014 
Weekly CEO Buys Highlight: OPK, RTRX, TFM, CSBK, AHP Apr 07 2014 
Three CEOs Reporting Large Insider Buys Apr 04 2014 
Steven Cohen Tops GuruFocus' Real Time Picks of the Week Apr 04 2014 
Morning Coffee: See Which Insiders are Buying Apr 04 2014 
Weekly CEO Buys Highlight: CLMS, OPK, OVAS, RTRX, MDCA Mar 17 2014 
Weekly CEO Buys Highlight: KMI, CLMS, RTRX, OPK, KO Mar 03 2014 

More From Other Websites
Top 10 Funds & Stocks at Risk of Being Squeezed in Market Turmoil Aug 25 2015
RETROPHIN, INC. Financials Aug 20 2015
United Therapeutics Sells Priority-Review Voucher to AbbVie Aug 19 2015
Retrophin Sues Founder Martin Shkreli For $65M. His Reply: 'Preposterous' Aug 18 2015
Citigroup, Retrophin, Eletrobras, Quindell Probe: Compliance Aug 18 2015
A Biotech Company Escalates the War Against Its Own Founder Aug 17 2015
RETROPHIN, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Aug 17 2015
Healthcare Fund Consonance Capital’s Top Picks For Q3 Following Monster First Half Aug 15 2015
10-Q for Retrophin Inc Aug 13 2015
RETROPHIN, INC. Files SEC form 10-Q, Quarterly Report Aug 10 2015
Edited Transcript of RTRX earnings conference call or presentation 4-Aug-15 8:30pm GMT Aug 05 2015
Retrophin reports 2Q loss Aug 04 2015
Retrophin reports 2Q loss Aug 04 2015
RETROPHIN, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 04 2015
Retrophin Reports Second Quarter 2015 Financial Results Aug 04 2015
Q2 2015 Retrophin Inc Earnings Release - After Market Close Aug 04 2015
RETROPHIN, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Jul 29 2015
Retrophin to Report Second Quarter 2015 Financial Results Jul 21 2015
Why This Analyst Expects New Alzhemier’s Trials Could Produce the Most Important Drugs in History Jul 21 2015
RETROPHIN, INC. Financials Jul 14 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK